FDA approves Kineret for the treatment of NOMID
CAPS is, in its most severe form of NOMID, a life-long and severely debilitating disease. The disease is associated with an overproduction of an immune system protein known as interleukin-1 (IL-1). Untreated patients develop progressive hearing and vision loss, variable degrees of cognitive impairment and joint contractures. Treatment of NOMID patients for 5 years with Kineret demonstrated that, in addition to controlling the daily symptoms of the disease such as fever, rash, headache and joint pain, important central nervous system (CNS) functions such as hearing and vision remain stable and do not progress on treatment.
"In order to prevent organ damage that results from untreated disease, we have learned that early diagnosis and the initiation of IL-1 blocking therapy are critical," said Dr. Raphaela Goldbach-Mansky, the principal investigator of the NOMID study that was conducted at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health (NIH) in Bethesda, MD, USA.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.